Biogen Increases Profit Forecast Amid Strong Demand for Rare Disease Medications

Reported 2 days ago

Biogen has raised its annual profit forecast and outperformed quarterly expectations due to robust demand for its rare disease drugs, despite a decline in sales of older multiple sclerosis treatments. The company's stock rose by 5.4% in premarket trading, as it exceeded sales projections for its Alzheimer's treatment Leqembi. Biogen anticipates a profit of $15.50 to $16.00 per share for 2025, up from its previous forecast, while also announcing a $2 billion investment in its North Carolina manufacturing facility to bolster domestic production amidst tariff challenges.

Source: YAHOO

View details

You may also interested in these wikis

Back to all Wikis